Hoppa till innehållet

OMXSPI+0,50%

S&P 500+0,80%

FTSE 100+0,54%

DAX+0,01%

NIKKEI+1,14%
Oncopeptides appoints Henrik Bergentoft as Chief Financial Officer

Stockholm – August 9, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the Company has appointed Henrik Bergentoft as Chief Financial Officer, CFO. Henrik was most recently CFO at RaySearch Laboratories and brings 20+ years of experience from leading finance roles at both medical and non-medical, publicly listed organizations. He will assume his new position during the fourth quarter, replacing Holger Lembrér.

“I am very happy that one of my first actions as CEO is to ask Henrik Bergentoft to join Oncopeptides, and I look forward to him taking on the role as CFO later this year,” says Sofia Heigis, CEO of Oncopeptides. “With his strong and varied background, I am sure that he will be a positive addition to our leadership team and I look forward to working closely with him to support the future growth of Oncopeptides.”

For more information, please contact:
David Augustsson, Director of Corporate Affairs, Oncopeptides AB (publ)
E-mail: david.augustsson@oncopeptides.com
Cell phone: +46 76 229 38 68

This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-09 08:40 CEST.

About Oncopeptides
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. 

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com. 

Attachments
Oncopeptides appoints Henrik Bergentoft as Chief Financial Officer

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera